Mana Bio Ltd Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2021

Location

Tel Aviv Israel

Primary Industry

Biotechnology

About

Based in Israel, and founded in 2021, Mana Bio Ltd, also known as Mana.bio, provides Lipid Nanoparticle-based delivery systems for various therapies. In October 2023, the company raised USD 19.5 million in seed funding co-led by Base4 Capital, Andreessen Horowitz, and Technion - Israel Institute of Technology and returning investors NFX and Lion Bird Fund. The company offers an artificial intelligence-based platform that combines machine learning and nanotechnology for the development of drug delivery systems for various therapies like vaccines and gene therapy. It helps develop gene therapy, which includes DNA and RNA-based therapeutics. Additionally, the firm also develops vaccines. The company plans to use the October 2023 funding to facilitate the development of its proprietary AI LNP platform to improve the delivery of RNA and gene therapies to extrahepatic tissues in the body.

Current Investors

NFX, Lion Bird Fund, Andreessen Horowitz

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Therapeutic Devices, Medical Software

Website

www.mana.bio

Verticals

Artificial Intelligence, Nanotechnology

Company Stage

Angel & Seed

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.